Efficacy and safety of an extended-release oxycodone (Remoxy®) formulation in patients with moderate to severe osteoarthritic pain

Journal of Opioid Management

Volumn 7, Issue 3, 2011, Pages 193-202

  Friedmann, Nadav ^a   Klutzaritz, Vicki ^a   Webster, Lynn ^b  

^a Pain Therapeutics Inc   (United States)

^b Lifetree Clinical Research   (United States)

Author keywords

Chronic pain; Osteoarthritis; Oxycodone extended release; Remoxy

Indexed keywords

OXYCODONE; PARACETAMOL;

ADULT; AGED; ANALGESIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CONSTIPATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FECES IMPACTION; FEMALE; GASTROINTESTINAL SYMPTOM; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; ORTHOSTATIC HYPOTENSION; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT DURATION; VOMITING; XEROSTOMIA;

ADULT; AGED; ANALGESICS, OPIOID; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HIP JOINT; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; OSTEOARTHRITIS; OXYCODONE; PAIN; PAIN MEASUREMENT; TREATMENT OUTCOME; VITAL SIGNS;

EID: 79960464697     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2011.0062     Document Type: Article

References (22)

1. Hardt J, Jacobsen C, Goldberg J, et al.: Prevalence of chronic pain in a representative sample in the United States. Pain Med. 2008; 9(7): 803-812.
2. Lawrence RC, Felson DT, Helmick CG, et al.: Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008; 58(1): 26-35.
3. Zhang W, Nuki G, Moskowitz RW, et al.: OARSI recommendations for the management of hip and knee osteoarthritis: Part 3: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010; 18(4): 476-499.
4. Caldwell JR, Hale ME, Boyd RE, et al.: Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: A double blind, randomized, multicenter, placebo controlled trial. J Rheumatol. 1999; 26(4): 862-869. (Pubitemid 29195674)
5. Portenoy RK, Farrar JT, Backonja MM, et al.: Long-term use of controlled-release oxycodone for noncancer pain: Results of a 3-year registry study. Clin J Pain. 2007; 23(4): 287-299. (Pubitemid 46650020)
6. Markenson JA, Croft J, Zhang PG, et al.: Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. Clin J Pain. 2005; 21(6): 524-535. (Pubitemid 41527742)
7. Roth SH, Fleischmann RM, Burch FX, et al.: Around-theclock, controlled-release oxycodone therapy for osteoarthritisrelated pain: Placebo-controlled trial and long-term evaluation. Arch Intern Med. 2000; 160(6): 853-860. (Pubitemid 30165247)
8. Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.
9. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons: Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009; 57(8): 1331-1346.
10. Bhamb B, Brown D, Hariharan J, et al.: Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006; 22(9): 1859-1865. (Pubitemid 44449242)
11. Nwokeji ED, Rascati KL, Brown CM, et al.: Influences of attitudes on family physicians' willingness to prescribe long-acting opioid analgesics for patients with chronic nonmalignant pain. Clin Ther. 2007; 29 (Suppl): 2589-2602. (Pubitemid 350299461)
12. Budman SH, Grimes Serrano JM, Butler SF: Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct J. 2009; 6: 8.
13. Katz NP, Adams EH, Chilcoat H, et al.: Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007; 23(8): 648-660. (Pubitemid 47462170)
14. Passik SD: Issues in long-term opioid therapy: Unmet needs, risks, and solutions. Mayo Clin Proc. 2009; 84(7): 593-601.
15. Aquina CT, Marques-Baptista A, Bridgeman P, et al.: OxyContin abuse and overdose. Postgrad Med. 2009; 121(2): 163-167.
16. Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34(3): 220-233. (Pubitemid 126433231)
17. Bellamy N, Buchanan WW, Goldsmith CH, et al.: Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol. 1988; 15(12): 1833-1840. (Pubitemid 19037656)
18. Avouac J, Gossec L, Dougados M: Efficacy and safety of opioids for osteoarthritis: A meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2007; 15(8): 957-965. (Pubitemid 47209257)
19. Zamloot M, Chao W, Kang L, et al.: Remoxy: A novel formulation of extended-release oxycodone developed using the ORADUR technology. J Appl Res. 2010; 10(3): 88-96.
20. Katz N: Enriched enrollment randomized withdrawal trial designs of analgesics: Focus on methodology. Clin J Pain. 2009; 25(9): 797-807.
21. Quessy SN: Two-stage enriched enrolment pain trials: A brief review of designs and opportunities for broader application. Pain. 2010; 148(1): 8-13.
22. Butera P, Klutzartiz V, Gilmore D, et al.: Long-term, 12-month, open-label phase III study of the safety of Remoxy® (oxycodone extended-release) in patients with moderate to severe chronic pain. Presented at the 25th Annual Meeting of the American Academy of Pain Medicine, Honolulu, Hawaii, 2009.